X-ray cross complementing group 1 (XRCC1) polymorphisms and bladder cancer risk has been investigated for years, but the result in Asian population is till inconclusive.
Thus, we performed this meta-analysis to determine the association of XRCC1 Arg194Trp, Arg280His, and Arg399Gln polymorphisms with bladder cancer risk in the Asian population. PubMed, EMBASE, and China National Knowledge Infrastructure were searched up to January 2013 to identify eligible studies. The association strength was measured with odd ratios (ORs) and 95 % confidence intervals (95 % CIs). A total of nine eligible studies, including 1,931 bladder cancer patients and 2,192 controls, were identified. Significant increased risk of bladder cancer was observed for Arg194Trp polymorphism (allele comparison OR = 1.20, 95 % CI: 1.06-1.36, Pheterogeneity = 0.11; dominant model OR = 1.20, 95 % CI: 1.02-1.41, Pheterogeneity = 0.37) and Arg280His polymorphism (heterozygote comparison OR = 1.87, 95 % CI: 1.21-2.90, Pheterogeneity = 0.01; dominant model OR = 1.75, 95 % CI: 1.05-2.90, Pheterogeneity = 0.01); however, Arg399Gln was not associated with susceptibility to bladder cancer. No evidence of publication bias was detected. Our meta-analysis results suggest that XRCC1 Arg194Trp and Arg280His polymorphisms are associated with significantly increased risk of bladder cancer in Asians.
Written by:
Zhang F, Wu JH, Zhao W, Liu HT. Are you the author?
Department of Urology, Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, 100 Haining Rd, Shanghai, 200080, People's Republic of China.
Reference: Tumour Biol. 2013 May 1. Epub ahead of print.
doi: 10.1007/s13277-013-0816-x
PubMed Abstract
PMID: 23636799
UroToday.com Investigative Urology Section
